Human GLP1R adenoviral particles

The glucagon-like peptide-1 receptor (GLP1R) gene encodes a G protein-coupled receptor (GPCR) that plays a key role in glucose metabolism and energy homeostasis. GLP1R is primarily expressed in pancreatic beta cells, the central nervous system, and gastrointestinal tissues. Activation of the receptor by its endogenous ligand, glucagon-like peptide-1 (GLP-1), triggers an intracellular signaling cascade that enhances glucose-dependent insulin secretion, inhibits glucagon release, and promotes satiety. These mechanisms make GLP1R a key therapeutic target for type 2 diabetes and obesity. In addition, GLP1R signaling has been associated with neuroprotection, cardiovascular health, and appetite regulation. Studying the structure, function, and downstream pathways of GLP1R is critical for developing novel therapeutics for metabolic and neurodegenerative diseases.

Human GLP1R adenoviral particles are genetically engineered viral vectors designed to deliver the human GLP1R gene to target cells or tissues for functional studies. Adenoviruses are ideal for gene delivery due to their high transduction efficiency, ability to infect both dividing and non-dividing cells, and ability to achieve stable transgene expression. These particles are replication-defective, ensuring safety in laboratory settings while maintaining high gene transfer efficiency. Human GLP1R adenoviral particles have been used by researchers to overexpress GLP1R in vitro or in vivo to study receptor signaling, ligand interactions, and downstream metabolic effects. Applications include screening for potential GLP1R agonists or antagonists, studying receptor trafficking, and modeling diseases such as diabetes.